TribsMab CLC, a novel bispecific antibody format solves a manufacturing challenge
Therapeutic mechanism that differs from conventional treatment methods with the target identified from genetic analysis of model animals and IC patients
Designed RANKL fragment peptides (Partial agonist of RANKL) treat fibrosis.
A small peptide that inhibits interaction between STAP-2 and TCR and exhibits immunosuppressive effects.
STAP-2 Inhibitory peptide suppresses tumor growth by inhibiting EGFR-STAP-2 interaction and promoting EGFR degradation.
A protein with the ability to both inhibit osteoclast differentiation and promote osteoblast differentiation
Inhibition of TLR4-dependent allergic inflammatory response by Asialoglycoprotein receptor (Asgr1) glycan ligands
Single Step Reaction, No Need of Genetic Modification
Anti-cell death, anti-fibrosis and induced-regeneration in fulminant hepatic failure and many kinds of Intractable liver diseases.
Original method and hepatocyte reproduced hepatobiliary function
RANKL fragment peptides treat psoriasis with reduced expression of inflammatory cytokines through Toll-like receptor 7/8 (TLR7/8) signaling pathway.
Fragmentation of RANKL Eliminates Side-effect while Boosting Effect.
About Bionauts.jp
